Kiniksa Pharmaceuticals Ltd (KNSA) - Total Liabilities
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has total liabilities worth $219.59 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Kiniksa Pharmaceuticals Ltd to assess how effectively this company generates cash.
Kiniksa Pharmaceuticals Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Kiniksa Pharmaceuticals Ltd to evaluate the company's liquid asset resilience ratio.
Kiniksa Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hugo Boss AG
F:BOSA
|
Germany | €2.06 Billion |
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677
|
China | CN¥253.36 Million |
|
Sai Gon Ha Noi Commercial Joint Stock Bank
VN:SHB
|
Vietnam | ₫859.26 Trillion |
|
BREVILLE GROUP LTD
F:HDE
|
Germany | €507.50 Million |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
China | CN¥4.78 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥3.24 Billion |
|
Elekta AB (publ)
ST:EKTA-B
|
Sweden | Skr19.67 Billion |
|
Santos Brasil Participações S.A
SA:STBP3
|
Brazil | R$4.72 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Kiniksa Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kiniksa Pharmaceuticals Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kiniksa Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual total liabilities of Kiniksa Pharmaceuticals Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $196.03 Million | +37.93% |
| 2024-12-31 | $142.12 Million | +62.45% |
| 2023-12-31 | $87.48 Million | +37.72% |
| 2022-12-31 | $63.52 Million | +33.00% |
| 2021-12-31 | $47.76 Million | +27.27% |
| 2020-12-31 | $37.53 Million | +28.92% |
| 2019-12-31 | $29.11 Million | -31.82% |
| 2018-12-31 | $42.70 Million | -68.88% |
| 2017-12-31 | $137.20 Million | +66.91% |
| 2016-12-31 | $82.20 Million | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more